Trial Profile
A Phase 2 Study of Single Agent Depsipeptide (FK228) in Gastric and Esophageal Cancers
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- 01 Jul 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 22 Jan 2013 Actual initiation date changed from Dec 2004 to Oct 2004 as reported by ClinicalTrials.gov.
- 22 Aug 2005 New trial record.